Clinical Trial Update: A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension [Phase 3]

View source ↗

Summary

Phase 3 long-term study of TAK-536 in children with hypertension has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• TAK-536

Snippet

Sponsor: Takeda | Conditions: Pediatric Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2019-12-23